These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22179721)

  • 21. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
    Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
    Kline MP; Rajkumar SV; Timm MM; Kimlinger TK; Haug JL; Lust JA; Greipp PR; Kumar S
    Leukemia; 2007 Jul; 21(7):1549-60. PubMed ID: 17460700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
    Zhang C; Cai TY; Zhu H; Yang LQ; Jiang H; Dong XW; Hu YZ; Lin NM; He QJ; Yang B
    Mol Cancer Ther; 2011 Jul; 10(7):1264-75. PubMed ID: 21566062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
    Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
    Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
    Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.
    Meynet O; Bénéteau M; Jacquin MA; Pradelli LA; Cornille A; Carles M; Ricci JE
    Leukemia; 2012 May; 26(5):1145-7. PubMed ID: 22076465
    [No Abstract]   [Full Text] [Related]  

  • 28. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
    Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
    Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
    Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF
    Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.
    Lawlor KE; Smith SD; van Nieuwenhuijze A; Huang DC; Wicks IP
    J Leukoc Biol; 2011 Oct; 90(4):819-29. PubMed ID: 21719460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
    Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
    Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
    Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
    Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
    Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.